Cytogenetic Prioritization With Inclusion of Molecular Markers Predicts Outcome in Previously Untreated Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine or Fludarabine Plus Cyclophosphamide: A Long-Term Follow-Up Study of the US Intergroup Phase III Trial E2997
Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2015.1023800
Full Text
Open PDFAbstract
Available in full text
Date
March 30, 2015
Authors
Publisher
Informa UK Limited